Table 6. Univariate analysis of AR, pARS578, PKC and pPKC expression and clinical outcome measures.
| Univariate analysis | |||
|---|---|---|---|
| Time to biochemical relapseP value Hazard Ratio (95% CI) | Survival from biochemical relapseP value Hazard Ratio (95% CI) | Disease-specific survivalP value Hazard Ratio (95% CI) | |
| AR Nuclear | 0.001, 2.84, (1.5-5.3) | 0.688, 1.18, (0.5-2.7) | 0.233, 1.44, (0.8-2.6) |
| AR Cytoplasmic | 0.466, 1.23, (0.7-2.2) | 0.922, 0.96, (0.4-2.1) | 0.517, 1.21, (0.7-2.2) |
| pARS578 Nuclear | 0.461, 1.30, (0.6-2.6) | 0.347, 1.62, (0.6-4.5) | 0.036, 2.24, (1.0-4.9) |
| pARS578 Cytoplasmic | 0.034, 2.1, (1.0-4.2) | 0.034, 3.19, (1.0-9.9) | <0.001, 4.54, (2.0-10.4) |
| PKC Nuclear | 0.712, 0.88, (0.4-1.8) | 0.450, 1.46, (0.5-3.9) | 0.203, 1.68, (0.8-3.7) |
| PKC Cytoplasmic | 0.938, 1.03, (0.5-2.1) | 0.799, 1.14, (0.4-3.1) | 0.269, 1.56, (0.7-3.5) |
| pPKC Nuclear | 0.764, 1.10, (0.6-2.0) | 0.403, 1.42, (0.6-3.2) | 0.890, 1.05, (0.6-2.0) |
| pPKC Cytoplasmic | 0.877, 0.96, (0.5-1.7) | 0.647, 0.82, (0.4-1.9) | 0.946, 0.98, (0.5-1.9) |
Univariate analysis of AR and pAR protein expression was carried out using Kaplan Meier methods with reference to the clinical outcome measures. Patients were considered to have biochemical relapse dependent on treatment; radical prostatectomy serum PSA >0.2ng/ml, radical radiotherapy serum PSA of 2.0ng/ml above the post treatment nadir level, hormone treatment 2-3 consecutive rises in serum PSA levels above the nadir obtained at intervals of >2 weeks [28, 29]. Numbers in bold denote significant associations with p value <0.05.